Eisai is focusing its six types of capital, including human and intellectual capital, on three key areas: dementia, oncology, and global health. To maximize our social impact and financial value, we are addressing 15 priority material topics. Through the development and delivery of innovative drugs and solutions created through these activities, we aim to effectively realize social good by relieving anxiety over health and reducing health disparities. Using this business model, our mission is to increase the satisfaction of patients and the people in the daily living domain, leading to the creation of financial value and the enhancement of these six types of capital. By continuously reinvesting in our mission-driven activities, we aim to achieve sustainable corporate value growth and increase in our price-to-book value ratio (PBR). We will create social impact by continuing sustainable efforts to realize our corporate concept, then reinvesting capital to further expand our social impact. This is Eisai’s social impact creation model.
